Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Background—In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Ticagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist that
blocks ADP‐induced platelet aggregation. Unlike thienopyridines, which irreversibly bind to …

Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine‐
5′‐diphosphate (ADP)‐mediated platelet aggregation in vivo. These compounds are …

Aims We sought to compare the results obtained from six major platelet function tests in the
assessment of the prevalence of aspirin resistance in patients with stable coronary artery …

Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

Aims The aim of this study was to determine whether platelet reactivity on clopidogrel
therapy, as measured by a point-of-care platelet function assay, is associated with …

Objectives: We investigated whether the loss of function CYP2C19 681G> A* 2
polymorphism is associated with high (> 14%) residual platelet aggregation (RPA) on …